PDLI R&D to Revenue
Pdl Biopharma Inc · R&D to Revenue
PDLI R&D to Revenue
Latest reported0.00%period ending
PDLI Quarterly R&D/Revenue (212.50% → 0.00%)
Latest values, visible window
High-resolution chart · PNG
PDLI r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 0% | |
| 28.1136% | |
| 30.9591% | |
| -21.4495% | |
| 9.7589% | |
| -3.9332% | |
| 2.2332% | |
| 1.7897% | |
| 1.0008% | |
| 1.4927% | |
| 2.0996% | |
| 1.0839% | |
| 1.0671% | |
| 3.0938% | |
| 4.4169% | |
| 3.094% | |
| 4.2914% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 57.8155% | |
| 36.1059% | |
| 83.1708% | |
| -27.8776% | |
| 50.8445% | |
| 48.6064% | |
| 51.5127% | |
| 60.6415% | |
| 63.6311% | |
| 60.0169% | |
| 68.2854% | |
| 54.3538% | |
| 64.5254% | |
| 51.8756% | |
| 90.8437% | |
| 132.2835% | |
| 138.1217% | |
| 124.1477% | |
| 119.549% | |
| 167.318% | |
| 241.3405% | |
| 100.2714% | |
| 72.0622% | |
| 146.6443% | |
| 218.6793% | |
| 99.8851% | |
| 61.4349% | |
| 91.9309% | |
| 74.7586% | |
| 56.386% | |
| 52.2392% | |
| 169.1635% | |
| 200.8082% | |
| 64.2799% | |
| 88.9076% | |
| 193.2203% | |
| 94.0476% | |
| 141.6667% | |
| 127.6923% | |
| 222.5% | |
| 92.7083% | |
| 123.7288% | |
| 355.5556% | |
| 361.1111% | |
| 136.9565% | |
| 252% | |
| 282.6087% | |
| 134% | |
| 212.5% |